updat model teva wake result provid latest
thought regard continu caution teva share name multipl expans
current ebitda near unlik view believ share
current level essenti give senior manag benefit doubt regard
abil drive improv gross margin gm long-term lt though
may come pass clear us enough drive lt ebitda stabil
 copaxon eros commerci disappoint associ ajovi
real potenti continu brisk austedo growth enough off-set
headwind reiter neutral rate rais pt model
align manag commentari regard gm
get stabil north american gener manag
essenti point contribut biosimilar launch gener version
gilead van buren truvada earli exclus opportun
report sale driver off-set steady-st retail
drive stabil regard biosimilar busi larg driven teva
rituxan biosimilar truxima launch last novemb sale
respect per iqvia manag note
reflect covid-rel disrupt teva suggest third parti data
good represent actual net sale
forteo look squar like opportun teva essenti guid fda
approv gener lilli forteo teriparatid late extent
approv inde happen time-frame teva could first substitut
gener though cover gain fda approv product via
last octob fda request addit compar data condit
grant ab-rat note radiu health cover
parathyroid hormon analog known tymlo market though differ
molecular entiti abaloparatid launch sale total note
forteo brand sale compar
latest color nuvar gener teva note clearli believ
final stage fda review file expect launch recal
amneal ow launch first gener version nuvar decemb
current volum share per iqvia enough capac captur
around overal volum author gener account volum
 plenti room teva take signific share reason good margin
brand sale
risk includ copaxon competit gener price risk
teva leader gener neurology-focus drug
ev/ebitda assum
cash debt
share outstand discount one
year
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
actual versu psc consensu estim
consensu estim
compani report factset psc research
compani report factset psc research
page
million except per share itemsactualspsc estimatesstreet estimatesnorth america market non-cor except per exhibit
consensu estim
compani report factset psc estim
current rate overweight price target base
ev/ebitda assum cash debt share
outstand discount risk includ price competit risk gener product
rais pt ev/ebitda discount one
year revis forecast
page
million except per america market non-cor consensu incom expens net share consensu teva quarterli annual incom statement
million except ep
sale
sell gener administr
incom loss tax
cog product revenu
expens total revenu
sell gener administr
sell gener administr
includ correct report revenu isra distribut busi onward correct also deduct cost sale relat isra distribut activ
teva alter revenu report methodolog result histor may reflect psc estim
includ sale teva proair ag sale ag includ gener segment
proprietari piper sandler may
current disclosur inform compani found http //www pipersandl com/researchdisclosur
